Trexquant Investment LP Syros Pharmaceuticals, Inc. Transaction History

Trexquant Investment LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$3.26 - $4.66 $98,328 - $140,554	-30,162 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$4.08 - $5.66 $14,337 - $19,889	-3,514 Reduced 10.43%	30,162 $135,000
Q2 2021 Aug 12, 2021	BUY	$5.01 - $7.48 $83,416 - $124,542	16,650 Added 97.79%	33,676 $184,000
Q1 2021 May 13, 2021	SELL	$7.19 - $14.95 $18,550 - $38,571	-2,580 Reduced 13.16%	17,026 $127,000
Q4 2020 Feb 11, 2021	BUY	$6.66 - $14.66 $130,575 - $287,423	19,606 New	19,606 $213,000
Q1 2020 May 08, 2020	SELL	$4.46 - $9.2 $59,545 - $122,829	-13,351 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$4.52 - $10.1 $60,346 - $134,845	13,351 New	13,351 $92,000
Q1 2019 May 13, 2019	SELL	$5.51 - $9.59 $229,144 - $398,819	-41,587 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$5.55 - $11.34 $230,807 - $471,596	41,587 New	41,587 $232,000
Q4 2017 Feb 09, 2018	SELL	$8.45 - $17.48 $161,724 - $334,549	-19,139 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$13.52 - $23.75 $258,759 - $454,551	19,139	19,139 $282,000

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Market Cap $43.1M
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.